OBJECTIVES: The only treatment for celiac disease (CD) is life-long adherence to a gluten-free diet (GFD). Noncompliance is associated with signs and symptoms of CD, yet long-term adherence rates are poor. It is not known how the burden of the GFD compares with other medical treatments, and there are limited data on the socioeconomic factors influencing treatment adherence. In this study, we compared treatment burden and health state in CD compared with other chronic illnesses and evaluated the relationship between treatment burden and adherence. METHODS: Survey was mailed to participants with CD, gastroesophageal reflux disease (GERD), irritable bowel syndrome, inflammatory bowel disease, hypertension (HTN), diabetes mellitus (DM), congestive heart failure, and end-stage renal disease (ESRD) on dialysis. Surveys included demographic information and visual analog scales measuring treatment burden, importance of treatment, disease-specific health status, and overall health status. RESULTS: We collected surveys from 341 celiac and 368 non-celiac participants. Celiac participants reported high treatment burden, greater than participants with GERD or HTN and comparable to ESRD. Conversely, patients with CD reported the highest health state of all groups. Factors associated with high treatment burden in CD included poor adherence, concern regarding food cost, eating outside the home, higher income, lack of college education, and time limitations in preparing food. Poor adherence in CD was associated with increased symptoms, income, and low perceived importance of treatment. CONCLUSIONS: Participants with CD have high treatment burden but also excellent overall health status in comparison with other chronic medical conditions. The significant burden of dietary therapy for CD argues for the need for safe adjuvant treatment, as well as interventions designed to lower the perceived burden of the GFD.
OBJECTIVES: The only treatment for celiac disease (CD) is life-long adherence to a gluten-free diet (GFD). Noncompliance is associated with signs and symptoms of CD, yet long-term adherence rates are poor. It is not known how the burden of the GFD compares with other medical treatments, and there are limited data on the socioeconomic factors influencing treatment adherence. In this study, we compared treatment burden and health state in CD compared with other chronic illnesses and evaluated the relationship between treatment burden and adherence. METHODS: Survey was mailed to participants with CD, gastroesophageal reflux disease (GERD), irritable bowel syndrome, inflammatory bowel disease, hypertension (HTN), diabetes mellitus (DM), congestive heart failure, and end-stage renal disease (ESRD) on dialysis. Surveys included demographic information and visual analog scales measuring treatment burden, importance of treatment, disease-specific health status, and overall health status. RESULTS: We collected surveys from 341 celiac and 368 non-celiac participants. Celiac participants reported high treatment burden, greater than participants with GERD or HTN and comparable to ESRD. Conversely, patients with CD reported the highest health state of all groups. Factors associated with high treatment burden in CD included poor adherence, concern regarding food cost, eating outside the home, higher income, lack of college education, and time limitations in preparing food. Poor adherence in CD was associated with increased symptoms, income, and low perceived importance of treatment. CONCLUSIONS:Participants with CD have high treatment burden but also excellent overall health status in comparison with other chronic medical conditions. The significant burden of dietary therapy for CD argues for the need for safe adjuvant treatment, as well as interventions designed to lower the perceived burden of the GFD.
Authors: Daniel A Leffler; Jessica Edwards-George; Melinda Dennis; Detlef Schuppan; Francis Cook; Debra L Franko; Jessica Blom-Hoffman; Ciaran P Kelly Journal: Dig Dis Sci Date: 2008-06 Impact factor: 3.199
Authors: Daniel A Leffler; Melinda Dennis; Jessica Edwards George; Shailaja Jamma; E Francis Cook; Detlef Schuppan; Ciaran P Kelly Journal: Clin Gastroenterol Hepatol Date: 2009-08-07 Impact factor: 11.382
Authors: Jessica B Edwards George; Daniel A Leffler; Melinda D Dennis; Debra L Franko; Jessica Blom-Hoffman; Ciaran P Kelly Journal: J Clin Gastroenterol Date: 2009-04 Impact factor: 3.062
Authors: Allison R Wilcox; Maria Concepcion C Dragnev; Christopher J Darcey; Corey A Siegel Journal: Inflamm Bowel Dis Date: 2010-04 Impact factor: 5.325
Authors: Gautam Goel; Tim King; A James Daveson; Jane M Andrews; Janakan Krishnarajah; Richard Krause; Gregor J E Brown; Ronald Fogel; Charles F Barish; Roger Epstein; Timothy P Kinney; Philip B Miner; Jason A Tye-Din; Adam Girardin; Juha Taavela; Alina Popp; John Sidney; Markku Mäki; Kaela E Goldstein; Patrick H Griffin; Suyue Wang; John L Dzuris; Leslie J Williams; Alessandro Sette; Ramnik J Xavier; Ludvig M Sollid; Bana Jabri; Robert P Anderson Journal: Lancet Gastroenterol Hepatol Date: 2017-05-11
Authors: Benjamin A Lerner; Lynn T Phan Vo; Shireen Yates; Andrew G Rundle; Peter H R Green; Benjamin Lebwohl Journal: Am J Gastroenterol Date: 2019-05 Impact factor: 10.864
Authors: Laura Kivelä; Alberto Caminero; Daniel A Leffler; Maria Ines Pinto-Sanchez; Jason A Tye-Din; Katri Lindfors Journal: Nat Rev Gastroenterol Hepatol Date: 2020-11-20 Impact factor: 46.802
Authors: David T Eton; Kathleen J Yost; Jin-Shei Lai; Jennifer L Ridgeway; Jason S Egginton; Jordan K Rosedahl; Mark Linzer; Deborah H Boehm; Azra Thakur; Sara Poplau; Laura Odell; Victor M Montori; Carl R May; Roger T Anderson Journal: Qual Life Res Date: 2016-08-26 Impact factor: 4.147